InvestSMART

ImExHS Limited (ASX:IME)

ALERT: Price-sensitive ASX Announcement for IME
Current share price for IME : $0.310 -0.04 (-11.43%)+
Announcement
Release
20 May 2026 9:20AM
Price at Release
$0.350
Full Release
download
Summary
The document provides a detailed overview of ImExHS Limited's financial performance and strategic initiatives discussed during their 2026 Annual General Meeting. The company reported financial growth with a revenue of $29 million for FY25, surpassing their guidance, and achieving an underlying EBITDA of $1.6 million. Notable progress includes expanding their AI platform Aquila+, which integrates five proprietary AI agents to automate the entire radiology workflow, thereby reducing costs and improving operational efficiency. The company also highlighted a strengthened leadership team and emphasized their commitment to growth in the Mexican market and beyond. Key resolutions included approving option grants for the CEO and additional share placement capacities. The outlook for FY26 is optimistic, with expectations to exceed previous year's EBITDA and maintain cash-positive operations. The focus remains on market expansion, technology development, and maintaining financial discipline.
Key Points
  • Revenue of $29 million for FY25, up 10% year-on-year.
  • Underlying EBITDA of $1.6 million, meeting the top end of guidance.
  • Development of Aquila+, an AI platform automating the full radiology workflow.
  • Appointment of new CTO and Sales Director to strengthen leadership.
  • Continued expansion into the Mexican market, supported by channel partners.
  • Approval of CEO option grants and additional share placement capacities.
  • Positive outlook for FY26 with expectations to exceed FY25 EBITDA.
  • Focus on market expansion, technology development, and financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.